Widely used:Recently Viewed
Clear AllToday’s Range
52 Week Range
Liquidity
Market cap
$957 Mln
Revenue (TTM)
$194 Mln
Net Profit (TTM)
$0 Mln
ROE
-0.3 %
ROCE
-- %
P/E Ratio
--
P/B Ratio
12.9
Industry P/E
27.54
EV/EBITDA
-6.4
Div. Yield
0 %
Debt to Equity
0
Book Value
$--
EPS
$-0.3
Face value
--
Shares outstanding
96,738,896
CFO
$-341.02 Mln
EBITDA
$-192.80 Mln
Net Profit
$-514.84 Mln
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
Avadel Pharmaceuticals PLC (AVDL)
| -10.7 | 0.0 | 18.0 | -38.5 | 56.9 | 3.2 | -7.3 |
|
BSE Sensex
| 3.7 | -1.6 | 9.6 | 5.9 | 14.3 | 19.1 | 11.9 |
|
Company
|
2024
|
2023
|
2022
|
2021
|
2020
|
2019
|
2018
|
|---|---|---|---|---|---|---|---|
|
Avadel Pharmaceuticals PLC (AVDL)
| -25.4 | 97.2 | -11.4 | 21.0 | -11.5 | 192.6 | -68.3 |
|
BSE Sensex
| 8.1 | 18.7 | 4.4 | 22.0 | 15.8 | 14.4 | 5.9 |
|
BSE Sensex
| 8.1 | 18.7 | 4.4 | 22.0 | 15.8 | 14.4 | 5.9 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Company |
Price ($) | Market Cap ($ Mln) | Revenue (TTM) | Net Profit (TTM) | OPM (%) | ROE (%) | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
|
Avadel Pharmaceuticals PLC (AVDL)
|
9.4 | 956.8 | 194.5 | -26.4 | -7.0 | -35.5 | -- | 12.9 |
| 20.7 | 5,221.1 | 459.4 | 206.8 | 25.6 | 68.3 | 26 | 13.3 | |
| 31.3 | 3,857.8 | 8.9 | -369.2 | -4,861.1 | -26.1 | -- | 2.9 | |
| 105.3 | 5,321.5 | 432.2 | -278.3 | -64.1 | -380.9 | -- | 100.0 | |
| 57.0 | 10,961.9 | 2,937.8 | 523.9 | 23.2 | 9.3 | 21.2 | 1.9 | |
| 39.7 | 7,414.9 | 127.4 | -668.0 | -432.9 | -- | -- | 123.7 | |
| 70.4 | 7,554.7 | 685.5 | 132.9 | 15.6 | 20.1 | 60.4 | 11.0 | |
| 14.0 | 7,087.1 | 4,427.0 | 373.0 | -0.7 | 5.8 | 18.5 | 1.1 | |
| 84.6 | 4,206.2 | 1,137.8 | 214.6 | 29.2 | 12.3 | 19.6 | 2.3 | |
| 9.1 | 10,539.7 | 14,317.0 | -3,790.1 | -23.7 | -21.4 | -- | 0.7 |
Avadel Pharmaceuticals plc operates as a biopharmaceutical company in the United States. Its lead product candidate is the LUMRYZ, a formulation of sodium oxybate, which is in a Phase 3 clinical trial for the treatment of cataplexy or excessive... daytime sleepiness in patients seven years of age and older with narcolepsy. The company was formerly known as Flamel Technologies SA and changed its name to Avadel Pharmaceuticals plc in January 2017. Avadel Pharmaceuticals plc was incorporated in 2015 and is headquartered in Dublin 2, Ireland. Address: 10 Earlsfort Terrace, Dublin, Ireland, D02 T380 Read more
CEO & Director
Mr. Gregory J. Divis Jr.
CEO & Director
Mr. Gregory J. Divis Jr.
Headquarters
Dublin
Website
Our rating system has guided millions of investors in the past 20 years.
The total asset value of Avadel Pharmaceuticals PLC (AVDL) stood at $ 219 Mln as on 31-Mar-25
The share price of Avadel Pharmaceuticals PLC (AVDL) is $9.39 (NASDAQ) as of 13-Jun-2025 11:37 EDT. Avadel Pharmaceuticals PLC (AVDL) has given a return of 56.92% in the last 3 years.
Avadel Pharmaceuticals PLC (AVDL) has a market capitalisation of $ 957 Mln as on 12-Jun-2025. As per Value Research classification, it is a company.
The P/B ratio of Avadel Pharmaceuticals PLC (AVDL) is 12.92 times as on 12-Jun-2025, a 170% premium to its peers’ median range of 4.78 times.
Since, TTM earnings of Avadel Pharmaceuticals PLC (AVDL) is negative, P/E ratio is not available.
Step 1. Open a demat account through a broker. You would need to provide your email, PAN, bank account details, aadhar details, etc., for KYC
Step 2. Sign in to the broker’s application through a mobile app or website. Use the Login ID and password provided by your broker.
Step 3. Transfer funds from your bank account into the wallet present in your brokerage account.
Step 4. Search for the Avadel Pharmaceuticals PLC (AVDL) and enter the required number of quantities and click on buy to purchase the shares of Avadel Pharmaceuticals PLC (AVDL).
Avadel Pharmaceuticals plc operates as a biopharmaceutical company in the United States. Its lead product candidate is the LUMRYZ, a formulation of sodium oxybate, which is in a Phase 3 clinical trial for the treatment of cataplexy or excessive daytime sleepiness in patients seven years of age and older with narcolepsy. The company was formerly known as Flamel Technologies SA and changed its name to Avadel Pharmaceuticals plc in January 2017. Avadel Pharmaceuticals plc was incorporated in 2015 and is headquartered in Dublin 2, Ireland. Address: 10 Earlsfort Terrace, Dublin, Ireland, D02 T380
The CEO & director of Mr. Gregory J. Divis Jr.. is Avadel Pharmaceuticals PLC (AVDL), and CFO & Sr. VP is Mr. Gregory J. Divis Jr..
There is no promoter pledging in Avadel Pharmaceuticals PLC (AVDL).
Some of the close peers are:
| Company | Market Cap($ Mln) |
|---|---|
|
1,089
|
|
|
1,022
|
|
|
742
|
|
|
722
|
|
|
667
|
|
|
542
|
|
|
485
|
|
|
419
|
|
|
415
|
| Avadel Pharmaceuticals PLC (AVDL) | Ratios |
|---|---|
|
Return on equity(%)
|
-35.51
|
|
Operating margin(%)
|
-6.99
|
|
Net Margin(%)
|
-13.58
|
|
Dividend yield(%)
|
--
|
No, TTM profit after tax of Avadel Pharmaceuticals PLC (AVDL) was $0 Mln.
$0.05
(
